Executive briefing: What is known—and what remains uncertain?

This article distills a 30-page review of 100 publications grouped into 12 themes, including 11 reader-designated core papers marked with a star. Antitumor research is the largest single topic. The collection also covers liver and kidney protection, metabolism, neuroprotection, and review articles. The number of papers in a topic should not be mistaken for proof of benefit.

The review classifies eight papers as clinically related, but that category also includes reviews, meta-analyses, and formulation or production research. The evidence base includes cell and animal experiments as well as human studies; the literature count alone does not establish efficacy.

Part 1 — The ingredient and its proposed mechanisms

C-phycocyanin (C-PC) is a blue, water-soluble phycobiliprotein found mainly in Arthrospira, commonly called Spirulina. Its chromophore is phycocyanobilin. The supplied review reports an absorption peak near 615 nm and emission near 640 nm. C-PC is sensitive to pH, heat, and light, which can cause fading or denaturation. Microencapsulation, spray drying, liposomes, nanocomposites, and electrospinning are among the stabilization or delivery approaches discussed.

Several pathways recur in laboratory research:

• Nrf2/HO-1: linked to antioxidant-enzyme defenses and reactive-oxygen control.
• NF-κB: studied in connection with inflammatory signaling.
• Bax, Bcl-2, and caspases: involved in the regulation of cell death.
• Ferroptosis and UCHL3: explored in particular injury models, including work on a peptide derived from C-PC.
• IRS-1/PI3K/AKT/mTOR: examined in cancer-cell growth and skeletal-muscle injury or fatigue models.
• Gut microbiota and immunity: an emerging area of investigation.

These findings come from different experimental models. They are mechanistic leads, not proof that the same effects occur in people or produce clinical benefits.

Part 2 — An informal evidence map

The categories below are a practical evidence summary, not a formal GRADE assessment.

Human studies: few, short, and product-specific

A triple-blind randomized trial assigned 80 people with relapsing-remitting multiple sclerosis to 1 g/day of whole Spirulina or placebo for 12 weeks. The study reported changes in inflammatory markers and some quality-of-life domains. Because participants received whole Spirulina, the findings cannot be attributed to isolated C-PC. Read the 2025 randomized trial.

A separate randomized safety study enrolled 24 adults and tested 2.3 g/day of a phycocyanin-enriched aqueous Spirulina extract—equivalent to about 1 g/day of phycocyanin—for two weeks. It focused on platelet activation and coagulation markers. It was not a disease-treatment trial and cannot establish long-term safety. Read the 2016 safety study.

Spirulina meta-analysis: informative, but not C-PC-specific

A systematic review and meta-analysis included eight trials (334 people) with type 2 diabetes. It reported changes in fasting glucose and some lipid measures, but no significant effect on HbA1c or post-meal glucose. Spirulina contains multiple compounds, so these results do not establish an effect of C-PC itself. Read the meta-analysis.

Cell and animal research: the largest body of disease-related work

Most disease-focused papers use cells or animal models. Such studies can help identify possible mechanisms and guide future trials, but cannot show that C-PC prevents or treats disease in people. They should be described as preclinical evidence.

Part 3 — Research areas, safety, and next steps

What the preclinical research is exploring

• Antioxidant and anti-inflammatory effects: cell and animal studies examine free-radical control, mitochondrial protection, lung inflammation, and tissue injury. COPD and asthma models report changes in inflammation, oxidative stress, or lung remodeling.
• Cardiovascular injury: a 2025 study tested P2, a peptide derived from C-PC, in mouse and cardiomyocyte models of myocardial ischemia-reperfusion injury. It explored ferroptosis and UCHL3. This is preclinical peptide research, not a human trial of intact C-PC. Read the P2 study.
• Metabolism and PCOS: studies include diabetes-related and diabetic-kidney models. A PCOS study used cells and mice to investigate an Nrf2-related ferroptosis pathway; it does not establish a treatment for people. Read the PCOS model study.
• Cancer: lung, breast, colorectal, and ovarian cancer models explore cell-cycle effects, apoptosis, and other mechanisms. One non-small-cell lung cancer paper tested C-PC in cells only. These results do not show that C-PC treats cancer in humans. Read the cell study.
• Neural, liver, and kidney protection: the literature mainly uses experimental injury or disease models, including damage induced by drugs or alcohol.

Product use and safety

Near-term product directions include natural blue food ingredients and functional foods. Cosmetics, topical formulations, sports nutrition, and wound-related uses remain exploratory. C-PC’s sensitivity to pH, heat, and light also creates practical challenges for manufacturing, storage, and delivery.

GRAS notifications or food-use authorizations apply to specified materials and conditions. They do not mean that C-PC is an FDA-approved medicine or establish a universal supplement dose. Research materials also vary: whole Spirulina, enriched extracts, purified protein, and peptides are not interchangeable.

Safety must be considered for the specific source, purity, formulation, and dose. A 2026 study in heat-stressed rabbits reported early embryonic loss with a particular nano-Spirulina preparation. This animal finding concerns a specific formulation and setting; it should not be generalized to all Spirulina or C-PC products. Read the rabbit study.

Conclusion

C-phycocyanin is a promising research ingredient, especially for food-color applications and mechanistic research. Its antioxidant and anti-inflammatory effects are supported mainly by experimental models, while claims about cancer, neurological disease, metabolic disorders, or organ protection remain unproven in humans. Future studies should clearly characterize the source and formulation, then test them in adequately powered randomized trials with longer follow-up and prespecified outcomes.

Evidence note: The supplied bibliography flags one retracted paper and some incomplete citation records. Core references should be checked individually before reuse.